Patents Examined by Jeffrey Parkin
  • Patent number: 10137187
    Abstract: The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent immune responses. In preferred embodiments of the compositions described herein, the DEN4 protein component is a dimeric form of DEN4. The compositions are designed to be acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. Also provided herein are methods of inducing a protective immune response in a human patient population by administering the compositions described herein to the patients.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: November 27, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Beth-Ann Griswold Coller, Vidya B. Pai, Jr., D. Elliot Parks, Michele Yelmene, Andrew J. Bett, Timothy Martyak
  • Patent number: 10087239
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: October 2, 2018
    Assignees: THERACLONE SCIENCES, INC., THE SCRIPPS RESEARCH INSTITUTE, INTERNATIONAL AIDS VACCINE INITIATIVE
    Inventors: Po-Ying Chan-Hui, Katherine Doores, Michael Huber, Stephen Kaminsky, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Majorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
  • Patent number: 10076567
    Abstract: The present invention relates to peptides and compositions suitable for use in inducing anti-HIV-1 antibodies. The compositions comprise HIV-1 gp41 membrane proximal external region (MPER) peptide-liposome conjugates for induction of broadly reactive anti-HIV-1 antibodies. The invention also relates to methods of inducing neutralizing anti-HIV-1 antibodies using such compositions.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: September 18, 2018
    Assignees: DUKE UNIVERSITY, LOS ALAMOS NATIONAL SECURITY, LLC
    Inventors: Barton F. Haynes, Bette T. Korber, S. Munir Alam
  • Patent number: 10053493
    Abstract: The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: August 21, 2018
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: William Messer, Ralph Baric, Aravinda de Silva, Boyd Yount
  • Patent number: 10047146
    Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: August 14, 2018
    Assignee: The Rockefeller University
    Inventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
  • Patent number: 10040826
    Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: August 7, 2018
    Assignees: DUKE UNIVERSITY, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Jerome Kim, Stephen Harrison, Barton F. Haynes, Georgia D. Tomaras, Nelson Michael
  • Patent number: 10039820
    Abstract: A West Nile virus vaccine for human use is described that preferably contains a recombinantly produced form of truncated West Nile virus envelope glycoprotein and aluminum adjuvant. The vaccine is acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. The vaccine is safe and effective for use in all healthy and at-risk populations. A pharmaceutically acceptable vehicle may also be included in the vaccine.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: August 7, 2018
    Assignee: Hawaii Biotech, Inc.
    Inventors: Beth-Ann Coller, Vidya Pai, Carolyn L. Weeks-Levy, Steven A. Ogata
  • Patent number: 10041946
    Abstract: The present invention is directed to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a sample. The combination immunoassays of the present invention employ a non-ionic detergent that effectively exposes or releases the HCV core antigen from virions in a sample without interfering with the performance of other reagents such as the capture of anti-HCV antibodies by recombinant HCV antigens.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: August 7, 2018
    Assignee: Ortho-Clinical Diagnostics Inc.
    Inventors: Jian Zheng, Jianping Yang
  • Patent number: 10034936
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: July 31, 2018
    Assignees: The University of Iowa Research Foundation, The United States of America as represented by the Secretary of the Department of Veterans Affairs
    Inventors: Jack T. Stapleton, Jinhua Xiang, Donna Klinzman, James H. McLinden
  • Patent number: 10035844
    Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: July 31, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
  • Patent number: 10005819
    Abstract: An approach of producing recombinant trimers that mimic native HIV-1 envelope trimers is developed. A recombinant protein forming the recombinant trimers encompasses a recombinant HIV-1 gp140 fused to a tag through a linker at C-terminus of the recombinant HIV-1 gp140. The linker is sufficiently long so that the tag is accessible for binding by a binding molecule bound on a solid matrix. After expressed in a cell, the recombinant protein is secreted into the culture medium and assembles into recombinant trimers therein. The recombinant trimers may be directly purified from the culture medium. Cleaved and uncleaved trimers from different clade viruses are produced.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: June 26, 2018
    Assignee: The Catholic University of America
    Inventors: Venigalla B. Rao, Wadad Alsalmi
  • Patent number: 9999664
    Abstract: The invention relates to an immunogenic HIV-1 gp120 mini V3 loop, which is a truncated version of the full-length gp120 V3 loop useful for crystallization with antibodies that recognize carbohydrate moieties. The invention also relates to the structure of a broadly neutralizing antibody as a complex with a glycosylated gp120 outer domain, as determined by crystallographic techniques, and the confirmation that a glycosylated gp120 outer domain has a functional relevant conformation, as well as the determination of key residues on a glycosylated gp120 outer domain, and uses thereof and compounds and compositions therefrom. Furthermore, the invention also relates to other peptides and mimetic peptides, which bind to broadly neutralizing antibodies.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: June 19, 2018
    Assignee: The Scripps Research Institute
    Inventors: Ian A. Wilson, Robyn L. Stanfield, Robert Pejchal
  • Patent number: 9993546
    Abstract: The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irrespective of whether the antigen is derived from a membrane or non-membrane protein. In one preferred aspect, the trafficking domain comprises a lumenal domain of a LAMP polypeptide. Alternatively, or additionally, the chimeric protein comprises a trafficking domain of an endocytic receptor (e.g., such as DEC-205 or gp200-MR6). The vaccines (DNA, RNA or protein) can be used to modulate or enhance an immune response against any kind of antigen. In one preferred aspect, the invention provides a method for treating a patient with cancer by providing a chimeric protein comprising a cancer-specific antigen or a nucleic acid encoding the protein to the patient.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: June 12, 2018
    Assignee: The Johns Hopkins University
    Inventors: Thomas August, Ernesto Marques, Jr.
  • Patent number: 9988424
    Abstract: The invention is generally directed to V1V2 immunogens.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: June 5, 2018
    Assignees: DUKE UNIVERSITY, U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND, NEW YORK UNIVERSITY
    Inventors: Barton F. Haynes, Huaxin Liao, Jerome Kim, Nelson Michael, Susan B. Zolla-Pazner
  • Patent number: 9969782
    Abstract: The present invention relates to an isolated immunogenic peptide chimera comprising a first peptide moiety comprising the amino acid sequence of SEQ ID NO: 1, or at least a contiguous 5 amino acid fragment thereof, a second peptide moiety comprising the amino acid sequence of SEQ ID NO: 2, or at least a contiguous 5 amino acid fragment thereof, and a linker joining the first and second peptide moieties, wherein the first peptide moiety is at the immunogenic peptide chimera's N-terminus and the second peptide moiety is at the immunogenic peptide chimera's C-terminus. Also disclosed is an immunogenic peptide including the amino acid sequence corresponding to SEQ ID NO: 6, or at least a contiguous 5 amino acid fragment thereof, having a length sufficient to form ?-hairpin structure.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: May 15, 2018
    Assignee: New York University
    Inventor: Timothy Cardozo
  • Patent number: 9951106
    Abstract: Fusion proteins comprising a portion of the HIV-1 Env protein (gp120 and gp140) and single-chain fragment V regions (ScFv) of an enhancing antibody that exhibits binding specificity for HIV-1 Env protein are disclosed that may serve in immunogenic formulations for vaccination against HIV-1 infection, as well as methods of generating an immune response using the fusion proteins.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: April 24, 2018
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Yongjun Guan, George Lewis, Anthony Devico, Mohammad Sajadi, Tongyun Liu, Marzena Pazgier
  • Patent number: 9944679
    Abstract: Provided herein are HIV vaccines that encompasses recombinant trimers that mimic native HIV-1 envelope trimers. Also provided are methods of administering to a subject in need thereof an HIV vaccine provided herein to elicit antibodies against a recombinant trimer in the subject. A recombinant trimer is formed by a recombinant protein comprising a recombinant HIV-1 gp140 fused to a tag through a linker at C-terminus of the recombinant HIV-1 gp140, wherein the linker is sufficiently long so that the tag is accessible for binding by a binding molecule bound on a solid matrix during purification of the recombinant trimer.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: April 17, 2018
    Assignee: The Catholic University of America
    Inventors: Venigalla B. Rao, Wadad Alsalmi
  • Patent number: 9938325
    Abstract: The present invention relates to a novel composition of HIV-1 Env proteins that contain structurally and immunologically distinct VI/V2 domains. Methods of isolating such proteins, and methods of using such proteins as immunogens, therapeutic agents, vaccines, and test compounds for use in identifying a HIV antiviral are also provided.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: April 10, 2018
    Assignee: Rutgers, The State University of New York
    Inventor: Abraham Pinter
  • Patent number: 9932370
    Abstract: The invention features isolated human immunodeficiency virus (HIV) envelope (Env) trimers, in which the amino acid sequence of the Env polypeptides is optimized to stabilize formation of the trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: April 3, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Dan H. Barouch, Joseph Patrick Nkolola
  • Patent number: 9920111
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: March 20, 2018
    Assignees: Theraclone Sciences, Inc., International Aids Vaccine Initiative, The Scripps Research Institute
    Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky